when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Hematology · news · pharmadog

← back to Hematology

News · Hematology

641 stories

Aug 26, 26Baxter Issues Voluntary Nationwide Recall for Two Lots of 0.9% Sodium Chloride Injection Due to Potential Presence of Particulate Matterfda medwatch

Aug 26, 26Percutaneous Catheter Recall: Boston Scientific Removes ENROUTE Transcarotid Neuroprotection Systemfda medwatch

Aug 25, 26FDA Authorizes First Wearable Device That Continuously Monitors Both Ketone Levels and Blood Sugarfda press

Aug 25, 26Roche, Eli Lilly get FDA nod for new Alzheimer’s blood testbiopharma dive

Aug 25, 26J&J’s Imaavy wins label expansion; Two approvals in Japanendpoints

Aug 25, 26STAT+: Pharmalittle: We’re reading about RFK Jr. vaccine disclosures, a Merck loss over Medicare prices, and morestat

Aug 25, 26Labcorp launches new hepatitis D test to find patients with most severe form of virusfiercebiotech

Aug 25, 26How Trump’s cuts are reshaping America’s health systemstat

Aug 25, 26Baxter Issues Voluntary Nationwide Recall for One Lot of 70% Dextrose Injection Due to Potential Presence of Particulate Matterfda medwatch

Aug 24, 26FDA extends review of Capricor cell therapy; Pain drug startup to go publicbiopharma dive

Aug 24, 26Boehringer Ingelheim suspends early study for pill candidate after ‘safety event’biospace

Aug 24, 26Opinion: Medicine stopped shaking hands. We should start againstat

Aug 24, 26Nurse practitioner trainees find themselves stymied by shortage of clinical mentorsstat

Aug 24, 26Roche, Eli Lilly net FDA approval for first-of-its-kind Alzheimer’s biomarker blood testfiercebiotech

Aug 24, 26Capricor, Replimune reviews signal FDA’s return to reliability but every application will stand alonebiospace

Aug 24, 26Recon: FDA clears Roche, Lilly Alzheimer’s blood tests; Regenxbio gene therapy trial halted by FDA againraps

Aug 21, 26Shareholder pressures Capricor; Lilly dives deeper into vaccinesbiopharma dive

Aug 21, 26Scientists deploy Merck’s Ebola vaccine in DRCstat

Aug 21, 26Novo Nordisk starts trialing lower maintenance doses of oral Wegovybiospace

Aug 21, 26Focal therapy for localized prostate cancer has divided physicians. Will new data change minds?stat

Aug 20, 26Ultragenyx, after setbacks, nabs first gene therapy approvalbiopharma dive

Aug 20, 26STAT+: Pharmalittle: We’re reading about a Regeneron rare disease drug, an Ultragenyx gene therapy, and morestat

Aug 20, 26FDA approves Ultragenyx's gene therapy Genglycos for glycogen storage disorderendpoints

Aug 20, 26Meet Aletta: The first FDA approved robotic blood draw devicefiercebiotech

Aug 19, 26FDA Approves First Therapy for Patients aged 8 years and older with Glycogen Storage Disease Type Iafda press

Aug 19, 26B. Braun Medical Inc. Issues Voluntary North American Recall of Excel® Lactated Ringers Injection, 1000mL Due to the Presence of Particulate Matterfda recalls

Aug 19, 26Amgen abandoning $500M+ Crohn’s collab won’t derail TScan’s pipeline strategyfiercebiotech

Aug 19, 26FDA Authorizes First-Of-Its-Kind Robotic Blood Draw Devicefda press

Aug 19, 26Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, morebiospace

Aug 19, 26Tolerance Bio jumps into phase 2 with $260M deal for thymus-targeting fusion proteinfiercebiotech

← prevpage 8 of 22next →